This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufacturing contracts, customers and consequences with regulators; as well as discussion around the ongoing issues with drug shortages and manufacturing challenges and whether it the move will help accelerate manufacturing for Wegovy and Ozempic.

Plus, what's next for Alzheimer's treatment following Biogen's withdrawal of Aduhelm?

As mentioned in this episode: you can subscribe to ClinicaSpace for our latest special edition on Leqembi.